Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy ; volume:19 ; number:1 ; day:20 ; month:7 ; year:2017 ; pages:1-10 ; date:12.2017
Arthritis Research & Therapy ; 19, Heft 1 (20.7.2017), 1-10, 12.2017
- Keyword
-
Orthopädie
- Creator
-
Teitsma, Xavier M.
- Contributor
-
Jacobs, Johannes W. G.
Mokry, Michal
Borm, Michelle E. A.
Pethö-Schramm, Attila
van Laar, Jacob M.
Bijlsma, Johannes W. J.
Lafeber, Floris P. J.
SpringerLink (Online service)
- DOI
-
10.1186/s13075-017-1378-x
- URN
-
urn:nbn:de:1111-2017082312046
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Teitsma, Xavier M.
- Jacobs, Johannes W. G.
- Mokry, Michal
- Borm, Michelle E. A.
- Pethö-Schramm, Attila
- van Laar, Jacob M.
- Bijlsma, Johannes W. J.
- Lafeber, Floris P. J.
- SpringerLink (Online service)
Other Objects (12)
Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
A minimal physiologically based pharmacokinetic model for high-dose methotrexate
Achieving parametric transparency in model-based factory planning
Methotrexate
General practitioner contributions to achieving sustained healthcare for offenders: a qualitative study
Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy
Personal sustained cooperation based on networked evolutionary game theory
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Blockchain-based solutions in achieving SDGs after COVID-19
Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
A minimal physiologically based pharmacokinetic model for high-dose methotrexate
Achieving parametric transparency in model-based factory planning
Methotrexate
General practitioner contributions to achieving sustained healthcare for offenders: a qualitative study
Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy
Personal sustained cooperation based on networked evolutionary game theory
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Blockchain-based solutions in achieving SDGs after COVID-19
Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
A minimal physiologically based pharmacokinetic model for high-dose methotrexate
Achieving parametric transparency in model-based factory planning
Methotrexate
General practitioner contributions to achieving sustained healthcare for offenders: a qualitative study
Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy
Personal sustained cooperation based on networked evolutionary game theory
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)